Nusinersen Sodium Patent Expiration

Nusinersen Sodium is Used for treating spinal muscular atrophy in infants and adults by increasing exon-7 inclusion in SMN2 mRNA. It was first introduced by Biogen Idec Inc in its drug Spinraza on Dec 23, 2016.


Nusinersen Sodium Patents

Given below is the list of patents protecting Nusinersen Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Spinraza US10266822 Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Dec 05, 2025 Biogen Idec
Spinraza US10436802 Methods for treating spinal muscular atrophy Sep 11, 2035 Biogen Idec
Spinraza US6166197 Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions Dec 26, 2017

(Expired)

Biogen Idec
Spinraza US6210892 Alteration of cellular behavior by antisense modulation of mRNA processing Oct 07, 2018

(Expired)

Biogen Idec
Spinraza US7101993 Oligonucleotides containing 2′-O-modified purines Sep 05, 2023

(Expired)

Biogen Idec
Spinraza US7838657 Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Jul 11, 2027 Biogen Idec
Spinraza US8110560 Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Dec 05, 2025 Biogen Idec
Spinraza US8361977 Compositions and methods for modulation of SMN2 splicing Dec 23, 2030 Biogen Idec
Spinraza US8980853 Compositions and methods for modulation of SMN2 splicing in a subject Nov 24, 2030 Biogen Idec
Spinraza US9717750 Compositions and methods for modulation of SMN2 splicing in a subject Jun 17, 2030 Biogen Idec
Spinraza US9926559 Compositions and methods for modulation of SMN2 splicing in a subject Jan 09, 2034 Biogen Idec


Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳